Desmoid tumors: To treat or not to treat, That is the question. Issue 24 (6th October 2020)

• Record Type: Journal Article
• Authors: Kasper, Bernd; Raut, Chandrajit P.; Gronchi, Alessandro
• Is Part Of: Cancer. Volume 126:Issue 24(2020)
• Page Start: 5213
• Page End: 5221
• Publication Date: 2020-10-06
• Subjects: β‐catenin -- CTNNB1 -- desmoid tumor -- The Desmoid Tumor Research Foundation (DTRF) -- European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) -- European Reference Network for Rare Solid Adult Cancers (EURACAN) -- medical therapy -- radiotherapy -- surgery; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.33233
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Desmoid tumors (DTs) are a rare disease of intermediate malignancy characterized histologically by a locally aggressive, monoclonal, fibroblastic proliferation and clinically by a variable and often unpredictable course. For decades, surgical resection has been the standard initial treatment approach; however, more recently, a paradigm shift toward a more conservative treatment strategy has been introduced. More than 5 years ago, The Desmoid Tumor Working Group started a consensus initiative in Europe with the aim of harmonizing the strategy among clinicians and setting up treatment recommendations for patients with DTs. This review summarizes the latest joint, global, evidence‐based guideline approach to DT management. Moreover, a number of gray areas in the treatment recommendations are discussed, and possible future perspectives on the treatment armamentarium for patients with DTs are presented. Abstract : The current review of desmoid tumors summarizes the recommendations for management and treatment strategies for this disease from the joint, global, evidence‐based, consensus guideline approach of The Desmoid Tumor Working Group and highlights future perspectives for these patients.